StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the biotechnology company's stock.

A number of other research analysts have also recently issued reports on CALA. SVB Leerink cut shares of Calithera Biosciences from an outperform rating to a market perform rating in a report on Tuesday, November 15th. LADENBURG THALM/SH SH lowered shares of Calithera Biosciences from a buy rating to a neutral rating in a report on Tuesday, November 15th.

Calithera Biosciences Stock Performance

Calithera Biosciences stock opened at $0.08 on Thursday. The firm has a market capitalization of $413,038.50, a P/E ratio of 0.00 and a beta of 1.05. The business has a 50-day moving average of $1.08 and a 200-day moving average of $2.25. Calithera Biosciences has a 1 year low of $0.07 and a 1 year high of $13.38.

Insiders Place Their Bets

In other news, Director Deepika Pakianathan sold 121,333 shares of the stock in a transaction on Friday, January 27th. The shares were sold at an average price of $0.39, for a total transaction of $47,319.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.60% of the company's stock.

Institutional Trading of Calithera Biosciences

Institutional investors have recently modified their holdings of the company. TSP Capital Management Group LLC grew its holdings in shares of Calithera Biosciences by 18.0% during the third quarter. TSP Capital Management Group LLC now owns 62,900 shares of the biotechnology company's stock worth $185,000 after buying an additional 9,605 shares in the last quarter. Renaissance Technologies LLC boosted its position in Calithera Biosciences by 13.8% during the 3rd quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company's stock worth $337,000 after acquiring an additional 13,855 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Calithera Biosciences by 143.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 72,865 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock valued at $415,000 after purchasing an additional 26,800 shares during the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Calithera Biosciences in the first quarter worth $404,000. 33.73% of the stock is currently owned by institutional investors.

About Calithera Biosciences

(Get Rating)

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.

Featured Articles

• Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
• MarketBeat Week in Review – 2/20 – 2/24
• Carvana Skidding On Revenue Decrease, Heavy Debt Burden
• What Are Consumer Staples Stocks?
• Is Rocky Brands Dividend A Good Fit For Your Portfolio?
• Beyond Meat Stock Is Not Beyond Hope

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.